Identification and Characterization of Human Colorectal Cancer Cluster Predominantly Expressing EP3 Prostanoid Receptor Subtype.

Biol Pharm Bull

Department of Pharmacology for Life Sciences, Graduate School of Pharmaceutical Sciences & Graduate School of Institute of Biomedical Sciences, Tokushima University.

Published: June 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Colorectal cancer (CRC) is one of the common types of cancer in humans. Prostaglandin E (PGE) is a well-known mediator of colorectal cancer through stimulation of four E-type prostanoid (EP) receptor subtypes: EP1, EP2, EP3, and EP4 receptors. All subtypes of EP receptors are involved in CRC promotion or malignancy. However, the characteristics of CRC that highly expresses EP receptor subtypes have not been clarified. In the present study, we classified CRC from a cancer genomic database and identified CRC clusters which highly express EP receptor subtypes. Most of these clusters predominantly expressed one subtype of EP receptor and showed different gene expression patterns. Among them, we focused on the cluster highly expressing the EP3 receptor (CL-EP3). As the result of characterization of gene expression, CL-EP3 was characterized as: epithelial mesenchymal transition (EMT)-induced progressed cancer with activation of transforming growth factor-β pathway, activation of hypoxia-inducible factor-1α, and suppression of runt-related transcription factor 3. Since we previously reported that EP3 receptor is involved in and induce colon cancer cell migration, EP3 receptor-expressing CRC may induce metastasis through these signaling pathways. Thus, the findings suggest the effectiveness of cancer clustering by gene expression of the EP receptor subtype to elucidate the mechanism of human CRC.

Download full-text PDF

Source
http://dx.doi.org/10.1248/bpb.b22-00104DOI Listing

Publication Analysis

Top Keywords

colorectal cancer
12
receptor subtypes
12
gene expression
12
cancer
8
expressing ep3
8
receptor
8
prostanoid receptor
8
receptor subtype
8
ep3 receptor
8
crc
7

Similar Publications

Gut microbiota dysbiosis in people living with HIV who have cancer: novel insights and diagnostic potential.

Front Immunol

September 2025

Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.

Background: People living with HIV(PLWH) are a high-risk population for cancer. We conducted a pioneering study on the gut microbiota of PLWH with various types of cancer, revealing key microbiota.

Methods: We collected stool samples from 54 PLWH who have cancer (PLWH-C), including Kaposi's sarcoma (KS, n=7), lymphoma (L, n=22), lung cancer (LC, n=12), and colorectal cancer (CRC, n=13), 55 PLWH who do not have cancer (PLWH-NC), and 49 people living without HIV (Ctrl).

View Article and Find Full Text PDF

Objective: The retrieval of 12 lymph nodes (LNs) remains a crucial criterion for accurate staging and prognosis evaluation in rectal cancer (RC). However, some patients fail to meet this threshold after surgery. This study developed a nomogram model based on clinical variables to predict the probability of retrieving 12 LNs postoperatively.

View Article and Find Full Text PDF

Background: Tumor deposit (TD) is an independent risk factor associated with recurrence or metastasis for patients with colorectal cancer (CRC). The scenario in which both TD and lymph node metastasis (LNM) are positive is not clearly illustrated by the current TNM staging system. Simply treating one TD as one or two LNMs by a weighting factor is inappropriate.

View Article and Find Full Text PDF

Introduction: Metastatic colorectal cancer (mCRC) exhibits significant heterogeneity in molecular profiles, influencing treatment response and patient outcomes. Mutations in v-raf murine sarcoma viral oncogene homolog B1 () and rat sarcoma () family genes are commonly observed in mCRC. Though originally thought to be mutually exclusive, recent data have shown that patients may present with concomitant and mutations, posing unique challenges and implications for clinical management.

View Article and Find Full Text PDF

Introduction: We identified potential approaches to address barriers to colorectal cancer (CRC) screening in rural communities of award recipients from the Centers for Disease Control and Prevention's Colorectal Cancer Control Program (CRCCP).

Methods: Nine program managers and directors discussed approaches to address barriers to CRC screening. The programs served areas with rural communities and tribal reservations.

View Article and Find Full Text PDF